All In MedTech

Device Trial Radar · NCT06731946

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 29, 2024

Primary completion

Oct 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Yibin FangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 13, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

Conditions

  • Intracranial Arterial Aneurysm

Interventions

  • Flow divertingDevice

    Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete aneurysm occlusion rateTime frame: 12(-3 ~ +6) months
  2. Favorable prognosis rateTime frame: 12(-3 ~ +6) months
  3. Procedure-related complication rateTime frame: 12(-3 ~ +6) months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Fourth People's Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.